Antisense-mediated exon skipping has made significant progress as a therapeutic platform in recent years. especially in the case of Duchenne muscular dystrophy (DMD). Despite FDA approval of eteplirsen-the first-ever antisense drug clinically marketed for DMD-exon skipping therapy still faces the significant hurdles of limited applicability and unknown truncated protein function. In-f... https://thebrickes.shop/product-category/bean-bag/